MedTrace Logo

Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer

NCT03412994 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-01-29

No results posted yet for this study

Summary

(1) Evaluate the efficacy of apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer. Whether it can prolong Progression Free Survival (PFS), overall survival (OS) in patients with advanced colorectal cancer and reduce symptoms and improve quality of life compared with standard second-line chemotherapy; (2) Observe the safety of apatinib for the treatment of advanced colorectal cancer.

Conditions

  • Colorectal Neoplasms

Interventions

DRUG

Apatinib

Apatinib in combination with standard second-line chemotherapy for advanced colorectal cancer

DRUG

standard second-line chemotherapy

The second line standard chemotherapy regimen recommended by the NCCN

Sponsors & Collaborators

  • Liqiang Zhong

    lead OTHER

Principal Investigators

  • Liqiang Zhong · Yibin Second People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-28
Primary Completion
2020-02-28
Completion
2021-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03412994 on ClinicalTrials.gov